$15.24
-$0.59(-3.72%)
*Data last updated: 2026-06-18 17:16 (UTC+8)
As of 2026-06-18 17:16, Viatris Inc (VTRS) is priced at $15.24, with a total market cap of $18.31B, a P/E ratio of -4.14, and a dividend yield of 3.05%. Today, the stock price fluctuated between $14.94 and $16.50. The current price is 2.00% above the day's low and 7.63% below the day's high, with a trading volume of 8.55M. Over the past 52 weeks, VTRS has traded between $10.73 to $17.54, and the current price is -13.11% away from the 52-week high.
VTRS Key Stats
Yesterday's Close$16.04
Market Cap$18.31B
Volume8.55M
P/E Ratio-4.14
Dividend Yield (TTM)3.05%
Dividend Amount$0.12
Diluted EPS (TTM)0.26
Net Income (FY)-$3.51B
Revenue (FY)$14.29B
Earnings Date2026-08-06
EPS Estimate0.62
Revenue Estimate$3.66B
Shares Outstanding1.14B
Beta (1Y)0.901
Ex-Dividend Date2026-05-22
Dividend Payment Date2026-06-17
About VTRS
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOScott Andrew Smith
HeadquartersCanonsburg,PA,US
Official Websitehttps://www.viatris.com
Employees (FY)30.00K
Average Revenue (1Y)$476.66K
Net Income per Employee-$117.16K
Viatris Inc (VTRS) FAQ
What's the stock price of Viatris Inc (VTRS) today?
x
Viatris Inc (VTRS) is currently trading at $15.24, with a 24h change of -3.72%. The 52-week trading range is $10.73–$17.54.
What are the 52-week high and low prices for Viatris Inc (VTRS)?
x
What is the price-to-earnings (P/E) ratio of Viatris Inc (VTRS)? What does it indicate?
x
What is the market cap of Viatris Inc (VTRS)?
x
What is the most recent quarterly earnings per share (EPS) for Viatris Inc (VTRS)?
x
Should you buy or sell Viatris Inc (VTRS) now?
x
What factors can affect the stock price of Viatris Inc (VTRS)?
x
How to buy Viatris Inc (VTRS) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.






